Welcome to the newest version of “Final week in Weed,” catching you up on the newest breaking information and trade developments on this planet of hashish.
Right here’s what you’ll have missed over the past week:
Ongoing Developments from Trump’s Hashish Rescheduling Govt Order
President Trump’s government order, signed on December 18, 2025, continued to generate dialogue and evaluation all through the week. The order directs the Lawyer Normal to expedite rescheduling marijuana from Schedule I to Schedule III underneath the Managed Substances Act, recognizing its accepted medical use whereas additionally selling expanded analysis on medical marijuana and cannabidiol (CBD). It additional requires a unified federal framework for hemp-derived cannabinoid merchandise, together with potential Medicare protection for sure CBD therapies and steering on THC limits.
Stories highlighted that rescheduling would offer fast tax reduction for state-legal hashish companies by eliminating Part 280E penalties, probably boosting profitability, however wouldn’t legalize marijuana federally or permit interstate commerce. Consultants famous that whereas the transfer might ease analysis obstacles and open doorways for real-world proof research, vital coverage adjustments from businesses would nonetheless be wanted to totally develop medical hashish investigations. Bipartisan lawmakers and stakeholders seen it as a significant step aligning federal coverage with state experiences and public assist, although many emphasised the necessity for additional reforms like banking entry and broader legalization.
Vireo Development Proclaims Main Acquisitions for Market Growth
Vireo Development Inc. made two vital acquisition bulletins in late December, signaling continued consolidation within the hashish sector. On December 22, the corporate entered a definitive settlement to accumulate Eaze Inc. for $47 million, including vertically built-in retail and supply operations in California, Florida, and Colorado. This deal expands Vireo’s footprint to 10 states with 166 dispensaries and roughly 800,000 sq. toes of cultivation and manufacturing capability, whereas enhancing its supply platform with Eaze’s historical past of over 12 million orders.
Earlier, on December 16, Vireo agreed to buy sure Colorado retail belongings from PharmaCann Inc. for $49 million, together with 17 dispensaries and the LivWell model, strengthening its place to 41 storefronts in that market. These transactions replicate a technique to realize scale in key areas amid regulatory shifts, with closures anticipated topic to approvals.
Oregon Pre-Roll Market Reveals Resilience Amid Flat General Gross sales
RollPros revealed its 2025 Pre-Roll Market Report for Oregon, offering detailed insights into the class’s efficiency from July to September 2025. Pre-roll income totaled $33.65 million, up 2.1% from the prior quarter and 27% since late 2022, regardless of a stagnant broader hashish market. Commonplace pre-rolls generated $21.45 million (up 0.3%), whereas infused pre-rolls reached $12.2 million (additionally up 0.3%).
Prime manufacturers by income included Portland Heights main, adopted by Sticks ($2.25 million, 6.7% share, 54% development), Hellavated, Benson Arbor (5.9% share, 3.8% development), and Kaprikorn (5.2% share, 18.5% development). Main merchandise favored hybrid multi-packs, equivalent to 1g 10-packs and 0.6g 12-packs. The report famous vital consolidation, with manufacturers lowered to 180 from prior highs, and automation advantages permitting high performers like Blackbird-produced SKUs to command greater costs. Shoppers prioritized worth (e.g., Sticks for funds choices), taste authenticity (Benson Arbor), and premium high quality (Kaprikorn, priced 35% above common per gram).
Hashish Shares Exhibit Blended Efficiency and Volatility
Hashish equities confirmed volatility within the remaining week of 2025, influenced by ongoing assessments of the rescheduling government order’s impacts. Main ETFs like AdvisorShares Pure US Hashish ETF (MSOS) skilled fluctuations, with some stories noting modest dips amid year-end changes and profit-taking following earlier rallies tied to the coverage shift.
Analysts pointed to cautious investor sentiment, weighing restricted short-term adjustments in opposition to potential long-term advantages like tax reduction and analysis enlargement. Firms tied to multi-state operators noticed assorted returns, reflecting broader market maturation and anticipation for 2026 implementation particulars.
Extra Coverage and State-Degree Notes
On December 24, Sen. John Hickenlooper (D-CO) launched a invoice to ascertain a federal fee on hashish regulation, modeled after alcohol insurance policies, to arrange for potential legalization. Different developments included particulars on a nascent federal CBD Medicare protection program and state-specific updates, equivalent to compliance steering and gross sales projections in maturing markets.
